SCHEMBL30344287

SCHEMBL30344287

Cc1cc([N+](=O)[O-])c(OC[C@@H]2CCN2C(=O)OC(C)(C)C)cc1Br

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 3/20 0.37
▸ NPSR1 Q6W5P4 1/20 0.37
▸ UCHL1 P09936 2/20 0.36
▸ ALOX5AP P20292 2/20 0.36
▸ GPR174 Q9BXC1 1/20 0.36
▸ USP30 Q70CQ3 1/20 0.35
▸ L3MBTL1 Q9Y468 1/20 0.35
▸ ALDH1A1 P00352 3/20 0.35
▸ MAPT P10636 2/20 0.35
▸ KMT2A Q03164 2/20 0.35
▸ KDM4E B2RXH2 1/20 0.35
▸ MEN1 O00255 1/20 0.35
▸ GLA P06280 1/20 0.35
▸ GAA P10253 1/20 0.35
▸ HPGD P15428 1/20 0.35
▸ TSHR P16473 1/20 0.35
▸ HSD17B10 Q99714 1/20 0.35
▸ MAPK1 P28482 1/20 0.35
▸ SMN1; SMN2 Q16637 1/20 0.35
▸ KCNH2 Q12809 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31360255 0.87 LMNA (0.37) LMNANPSR1ALOX5APGPR174L3MBTL1
SCHEMBL30344383 0.87 LMNA (0.37) LMNANPSR1ALOX5APGPR174L3MBTL1
SCHEMBL30344637 0.87 LMNA (0.37) LMNAALDH1A1MAPTKMT2AKDM4E
SCHEMBL30344830 0.86 PDGFRB (0.41) LMNANPSR1UCHL1GPR174USP30
SCHEMBL31663771 0.75 CHRNB4 (0.41) LMNANPSR1UCHL1ALOX5APL3MBTL1
SCHEMBL29619117 0.75 CHRNB4 (0.41) LMNANPSR1UCHL1ALOX5APL3MBTL1
SCHEMBL31615587 0.75 DPP4 (0.45) LMNANPSR1ALOX5APALDH1A1KDM4E
SCHEMBL29619082 0.75 CHRNB4 (0.41) LMNANPSR1UCHL1ALOX5APL3MBTL1
SCHEMBL19030212 0.75 CYP1A2 (0.40) LMNAALDH1A1MAPTKMT2AMAPK1
SCHEMBL14941693 0.74 ALOX5AP (0.39) UCHL1ALOX5APUSP30KDM4EHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250025443-A1 COMPOUNDS AND METHODS FOR TREATING CORONA VIRUSES Clear Creek Bio, Inc. (US) 2025-01-23 — — US disclosed
WO-2023064493-A1 COMPOUNDS AND METHODS FOR TREATING CORONAVIRUSES Clear Creek Bio, Inc. (US) 2023-04-20 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250025443-A1 COMPOUNDS AND METHODS FOR TREATING CORONA VIRUSES ACE, PREP, PEPD LMNA 627/4885NPSR1 380/4885UCHL1 431/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback